We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Qiagen (QGEN - Free Report) will report quarterly earnings of $0.44 per share in its upcoming release, pointing to a year-over-year decline of 17%. It is anticipated that revenues will amount to $454.97 million, exhibiting a decline of 6.3% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Qiagen metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' should come in at $11.44 million. The estimate indicates a change of -12% from the prior-year quarter.
The consensus estimate for 'Sales by Product Groups- Genomics / NGS' stands at $50.95 million. The estimate indicates a change of -7.4% from the prior-year quarter.
The average prediction of analysts places 'Sales by Product Groups- PCR / Nucleic acid amplification' at $70.87 million. The estimate indicates a change of -8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales by Product Groups- Other' should arrive at $11.67 million. The estimate suggests a change of -31.4% year over year.
It is projected by analysts that the 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' will reach $23.82 million. The estimate indicates a change of +13.4% from the prior-year quarter.
Analysts' assessment points toward 'Sales by Product Groups- Sample technologies' reaching $146.53 million. The estimate points to a change of -15.3% from the year-ago quarter.
Analysts expect 'Sales by Product Groups- Diagnostic solutions' to come in at $174.25 million. The estimate points to a change of +6.9% from the year-ago quarter.
Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' to reach $105.61 million. The estimate points to a change of +14.8% from the year-ago quarter.
Analysts predict that the 'Revenue- Molecular Diagnostics' will reach $247.55 million. The estimate suggests a change of -1% year over year.
Over the past month, shares of Qiagen have returned -1.9% versus the Zacks S&P 500 composite's -3% change. Currently, QGEN carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Qiagen (QGEN - Free Report) will report quarterly earnings of $0.44 per share in its upcoming release, pointing to a year-over-year decline of 17%. It is anticipated that revenues will amount to $454.97 million, exhibiting a decline of 6.3% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Qiagen metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' should come in at $11.44 million. The estimate indicates a change of -12% from the prior-year quarter.
The consensus estimate for 'Sales by Product Groups- Genomics / NGS' stands at $50.95 million. The estimate indicates a change of -7.4% from the prior-year quarter.
The average prediction of analysts places 'Sales by Product Groups- PCR / Nucleic acid amplification' at $70.87 million. The estimate indicates a change of -8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales by Product Groups- Other' should arrive at $11.67 million. The estimate suggests a change of -31.4% year over year.
It is projected by analysts that the 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' will reach $23.82 million. The estimate indicates a change of +13.4% from the prior-year quarter.
Analysts' assessment points toward 'Sales by Product Groups- Sample technologies' reaching $146.53 million. The estimate points to a change of -15.3% from the year-ago quarter.
Analysts expect 'Sales by Product Groups- Diagnostic solutions' to come in at $174.25 million. The estimate points to a change of +6.9% from the year-ago quarter.
Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' to reach $105.61 million. The estimate points to a change of +14.8% from the year-ago quarter.
Analysts predict that the 'Revenue- Molecular Diagnostics' will reach $247.55 million. The estimate suggests a change of -1% year over year.
View all Key Company Metrics for Qiagen here>>>
Over the past month, shares of Qiagen have returned -1.9% versus the Zacks S&P 500 composite's -3% change. Currently, QGEN carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>